Use of the complement inhibitor Coversin to treat HSCT-associated TMA
作者
Timothy H.J. Goodship,Fernando Pinto,Wynne Weston‐Davies,Juliana Silva,Jun‐ichi Nishimura,Miles A. Nunn,Ian J. Mackie,Samuel J. Machin,Liina Palm,Jeremy W. Pryce,Robert Chiesa,Persis Jal Amrolia,Paul A. Veys
Finding an inherited complement abnormality in HSCT-associated TMA provides a rationale for the use of a complement inhibitor.Alternative complement inhibitors such as Coversin should be considered in patients who are resistant to eculizumab.